山東路橋(000498.SZ):子公司聯合體中標52.96億元公路施工項目
格隆匯3月4日丨山東路橋(000498.SZ)公佈,近日,公司子公司路橋集團、子公司公路橋樑公司組成的聯合體被確定為濟南至微山公路濟寧新機場至棗菏高速段工程施工項目施工一標段(JWSG-ZX)第一中標候選人。目前,上述項目定標工作已經完成。2020年3月3日,招標單位發佈了《濟南至微山公路濟寧新機場至棗菏高速段工程施工招標中標結果》。
根據招標單位山東高速建設管理集團有限公司發佈的招標中標結果,施工一標段(JWSG-ZX)中標單位為:牽頭方公路橋樑公司、聯合方路橋集團。中標標價約為52.96億元,約佔公司2018年度經審計營業收入的35.86%;項目施工期36個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.